دورية أكاديمية
Perceptions, prevalence, and patterns of cannabis use among cancer patients treated at 12 NCI-Designated Cancer Centers.
| العنوان: | Perceptions, prevalence, and patterns of cannabis use among cancer patients treated at 12 NCI-Designated Cancer Centers. |
|---|---|
| المؤلفون: | Ellison GL; Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, MD, USA., Helzlsouer KJ; Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, MD, USA., Rosenfield SM; Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, MD, USA., Kim Y; ICF, Rockville, MD, USA., Ashare RL; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.; Department of Psychology, University of Buffalo, Buffalo, NY, USA., Blaes AH; Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN, USA., Cullen J; Case Comprehensive Cancer Center, Cleveland, OH, USA.; Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA., Doran N; University of California, San Diego, Health Moores Cancer Center, La Jolla, CA, USA.; Department of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA, USA.; Psychology Service, Jennifer Moreno Veterans Affairs Medical Center, San Diego, CA, USA., Ebbert JO; Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA., Egan KM; Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Heffner JL; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Lee RT; Case Comprehensive Cancer Center, Cleveland, OH, USA.; City of Hope Comprehensive Cancer Center, Duarte, CA, USA., McClure EA; Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA.; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA., McDaniels-Davidson C; University of California, San Diego, Health Moores Cancer Center, La Jolla, CA, USA.; Division of Health Promotion and Behavioral Science, School of Public Health, San Diego State University, San Diego, CA, USA., Meghani SH; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.; Department of Biobehavioral Health Sciences, NewCourtland Center for Transitions and Health Leonard Davis Institute for Health Economics, University of Pennsylvania, Philadelphia, PA, USA., Newcomb PA; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Nugent S; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.; Department of Psychiatry, Oregon Health & Science University, Portland, OR, USA., Hernandez-Ortega N; Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL, USA.; School of Nursing and Health Studies, University of Miami, Coral Gables, FL, USA., Salz T; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Vidot DC; Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL, USA.; School of Nursing and Health Studies, University of Miami, Coral Gables, FL, USA., Worster B; Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA, USA., Zylla DM; The Cancer Research Center, HealthPartners and Park Nicollet, Minneapolis, MN, USA. |
| المصدر: | Journal of the National Cancer Institute. Monographs [J Natl Cancer Inst Monogr] 2024 Aug 15; Vol. 2024 (66), pp. 202-217. |
| نوع المنشور: | Journal Article; Multicenter Study |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 9011255 Publication Model: Print Cited Medium: Internet ISSN: 1745-6614 (Electronic) Linking ISSN: 10526773 NLM ISO Abbreviation: J Natl Cancer Inst Monogr Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2003-> : Cary Nc : Oxford University Press Original Publication: Bethesda, MD : U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health ; Washington, DC : For sale by the Supt. of Docs., U.S. G.P.O., [1990- |
| مواضيع طبية MeSH: | Neoplasms*/epidemiology , Neoplasms*/psychology , Neoplasms*/therapy , Medical Marijuana*/therapeutic use , Medical Marijuana*/adverse effects, Humans ; Female ; Male ; United States/epidemiology ; Middle Aged ; Prevalence ; Adult ; National Cancer Institute (U.S.) ; Surveys and Questionnaires ; Cancer Care Facilities/statistics & numerical data ; Aged ; Perception |
| مستخلص: | Background: The legal climate for cannabis use has dramatically changed with an increasing number of states passing legislation legalizing access for medical and recreational use. Among cancer patients, cannabis is often used to ameliorate adverse effects of cancer treatment. Data are limited on the extent and type of use among cancer patients during treatment and the perceived benefits and harms. This multicenter survey was conducted to assess the use of cannabis among cancer patients residing in states with varied legal access to cannabis. Methods: A total of 12 NCI-Designated Cancer Centers, across states with varied cannabis-access legal status, conducted surveys with a core questionnaire to assess cannabis use among recently diagnosed cancer patients. Data were collected between September 2021 and August 2023 and pooled across 12 cancer centers. Frequencies and 95% confidence intervals for core survey measures were calculated, and weighted estimates are presented for the 10 sites that drew probability samples. Results: Overall reported cannabis use since cancer diagnosis among survey respondents was 32.9% (weighted), which varied slightly by state legalization status. The most common perceived benefits of use were for pain, sleep, stress and anxiety, and treatment side effects. Reported perceived risks were less common and included inability to drive, difficulty concentrating, lung damage, addiction, and impact on employment. A majority reported feeling comfortable speaking to health-care providers though, overall, only 21.5% reported having done so. Among those who used cannabis since diagnosis, the most common modes were eating in food, smoking, and pills or tinctures, and the most common reasons were for sleep disturbance, followed by pain and stress and anxiety with 60%-68% reporting improved symptoms with use. Conclusion: This geographically diverse survey demonstrates that patients use cannabis regardless of its legal status. Addressing knowledge gaps concerning benefits and harms of cannabis use during cancer treatment is critical to enhance patient-provider communication. (Published by Oxford University Press 2024.) |
| References: | J Palliat Med. 2019 Oct;22(10):1224-1226. (PMID: 30994387) J Addict Med. 2020 Jul/Aug;14(4):337-344. (PMID: 31821192) Cancer. 2023 Nov 1;129(21):3498-3508. (PMID: 37354093) Cancers (Basel). 2022 Apr 13;14(8):. (PMID: 35454955) J Natl Cancer Inst Monogr. 2021 Nov 28;2021(58):35-38. (PMID: 34850895) Cancer. 2019 Jul 1;125(13):2242-2251. (PMID: 31006849) Eur J Cancer. 2023 Feb;180:52-61. (PMID: 36535195) BMC Cancer. 2022 Mar 24;22(1):319. (PMID: 35331185) Gynecol Oncol Rep. 2019 Sep 09;30:100497. (PMID: 31692541) Support Care Cancer. 2023 Mar 6;31(4):202. (PMID: 36872397) Nurs Outlook. 2021 Jul-Aug;69(4):672-685. (PMID: 33581859) J Oncol Pract. 2018 Sep;14(9):e566-e578. (PMID: 30205775) Am J Clin Oncol. 2020 Sep;43(9):636-639. (PMID: 32889833) Cancer. 2017 Nov 15;123(22):4488-4497. (PMID: 28944449) Subst Abus. 2023 Jul;44(3):249-260. (PMID: 37728136) Support Care Cancer. 2023 Jun 29;31(7):429. (PMID: 37382737) Oncologist. 2019 Apr;24(4):549-554. (PMID: 30670598) Medicines (Basel). 2018 Dec 23;6(1):. (PMID: 30583596) Dialogues Clin Neurosci. 2020 Sep;22(3):223-228. (PMID: 33162765) PLoS One. 2021 Mar 16;16(3):e0248227. (PMID: 33725004) Subst Use Misuse. 2022;57(3):432-441. (PMID: 34986066) Ann Am Thorac Soc. 2013 Jun;10(3):239-47. (PMID: 23802821) Cancer. 2022 Jan 01;128(1):160-168. (PMID: 34636036) J Oncol Pract. 2019 Apr;15(4):e338-e345. (PMID: 30860938) |
| معلومات مُعتمدة: | P30 CA056036 United States CA NCI NIH HHS; United States NH NIH HHS; United States HH HHS; P30CA016520 12 NCI-Designated Cancer Centers |
| المشرفين على المادة: | 0 (Medical Marijuana) |
| تواريخ الأحداث: | Date Created: 20240807 Date Completed: 20240807 Latest Revision: 20240830 |
| رمز التحديث: | 20240830 |
| مُعرف محوري في PubMed: | PMC11303851 |
| DOI: | 10.1093/jncimonographs/lgae029 |
| PMID: | 39108244 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!